Michele D. V.
- Country
- Italy
- Department
- SS Oncologia Medica Melanomi
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Neoadjuvant Immunotherapy with Nivolumab, Ipilimumab, MDNA11, and Tocilizumab in High-Risk Resectable Melanoma: A Phase Ib Multicentre Randomised Trial
Data & Insights
Has run more than one trial at 190 of 310 partner sites.
Specializations
Advanced Melanoma Studies
This investigator specializes in clinical research focused on advanced and metastatic melanoma, with particular emphasis on evaluating novel therapeutic approaches for previously untreated and treatment-resistant cases.
- Unresectable Melanoma
- Metastatic Disease Management
- BRAF V600E/K Mutation-Positive Cases
Targeted Therapies
The investigator conducts research on combination immunotherapy treatments and targeted molecular approaches, including studies of novel drug combinations and therapeutic regimens.
- Immunotherapy Combinations
- NRAS Mutant Melanoma
- PD-1 Refractory Cases
Specialized Melanoma Types
Research extends to distinct melanoma subtypes, including uveal melanoma and cases with brain metastases, exploring innovative treatment strategies for these specific presentations.
- Ocular Melanoma Treatment
- Brain Metastasis Management
- High-Risk Resectable Disease
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.